LORENZ, Katrin, STRÜSSMANN, Tim, TREPEL, Martin, ILLERHAUS, Gerald, PELZ, Henning, SCHOLZ, Catherine, DUYSTER, Justus und MARKS, Reinhard, 2024. PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity. Freiburg: Universität.
Elsevier - Harvard (with titles)Lorenz, K., Strüßmann, T., Trepel, M., Illerhaus, G., Pelz, H., Scholz, C., Duyster, J., Marks, R., 2024. PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity. Universität, Freiburg. https://doi.org/10.1097/01.hs9.0000851336.89795.74
American Psychological Association 7th editionLorenz, K., Strüßmann, T., Trepel, M., Illerhaus, G., Pelz, H., Scholz, C., Duyster, J., & Marks, R. (ca. 2024). PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity [Cd]. Universität. https://doi.org/10.1097/01.hs9.0000851336.89795.74
Springer - Basic (author-date)Lorenz K, Strüßmann T, Trepel M, Illerhaus G, Pelz H, Scholz C, Duyster J, Marks R (2024) PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Lorenz, Katrin/ Strüßmann, Tim/ Trepel, Martin/ Illerhaus, Gerald/ Pelz, Henning/ Scholz, Catherine/ Duyster, Justus/ Marks, Reinhard, PB2126: R-CPOP as first line treatment for DLBCL patients with significant reduced LVEF or high risk of anthracycline induced cardiotoxicity, Freiburg 2024.